• KOL
    • Hepatic Encephalopathy
    • Karin Weissenborn
    • Karin Weissenborn: Influence Statistics

      Karin Weissenborn

      Karin Weissenborn

      Show email address

      Department of Neurology, Hannover Medical School, Hannover, Germany. | Department of Neurology, Hannover Medical School, Germany. (G.M.G., N.B., J.E., A.L., M.M.G., T.v.G., ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Karin Weissenborn:Expert Impact

      Concepts for whichKarin Weissenbornhas direct influence:Hepatic encephalopathy,Liver transplantation,Ischemic stroke,Atrial fibrillation,Embolic stroke,Patients liver transplantation,Kidney transplantation,Minimal hepatic encephalopathy.

      Karin Weissenborn:KOL impact

      Concepts related to the work of other authors for whichfor which Karin Weissenborn has influence:Hepatic encephalopathy,Liver cirrhosis,Cirrhotic patients,Ischemic stroke,Cognitive impairment,Spot sign,Portal hypertension.

      KOL Resume for Karin Weissenborn

      Year
      2022

      Department of Neurology, Hannover Medical School, Hannover, Germany.

      2021

      Department of Neurology, and.

      Clinic for Neurology, Hannover Medical School, Hannover, Germany

      2020

      Department of Neurology, Hannover Medical School, Hannover.

      Integrated Research and Treatment Centre Transplantation, Hannover Medical School, Hannover, Germany

      2019

      Department of Neurology, Hannover Medical School, Hannover, Germany; Integrated Research and Treatment Centre Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany.

      University Hospital, Neurology, Hannover, Germany

      2018

      Integrated Research and Treatment Centre Transplantation (IFB‐Tx), Hannover Medical School, Hannover, Germany

      From the Department of Neurology (G.M.G., H.W., K.W.).

      2017

      Hannelore Barg-Hock, Jürgen Klempnauer, Clinic for Visceral and Transplant Surgery, Hannover Medical School, 30625 Hannover, Germany

      Klinik für Neurologie, Medizinische Hochschule Hannover, Hannover.

      Departments of Neurology

      Integrated Research and Treatment Centre Transplantation

      2016

      Integrated Research and Treatment Centre Transplantation, Hannover Medical School, Hannover, Germany.

      From the Clinic for Neurology (RS, JM, MD, HW, ABT, KS, KW); Clinic for Nephrology (EB, JTK); and Institute for Interventional and Diagnostic Neuroradiology, Hannover Medical School, Hannover, Germany (AMG, HL).

      Department of Neurology, Hannover Medical School, 30625 Hannover, Germany;, (G.M.G.);, (R.S.);, (M.D.);, (H.W.)

      Hannover Medical School Clinic for Neurology Hannover Germany

      2015

      Integrated Research and Treatment Centre Transplantation, Hannover, Germany.

      Department of Neurology, Hannover Medical School, 30623, Hannover, Germany

      2014

      Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany

      2013

      From the Departments of Neurology (N.L., Y.F.L., Y.L.W., Y.J.W., X.Q.Z.) and Neuroradiology (L.M., Y.P.G.), Beijing Tiantan Hospital, Capital Medical University, Beijing, China; the Departments of Neurology (N.L., H.W., R.D., K.W.) and Interventional and Diagnostic Neuroradiology (P.R.), Hannover Medical School, Hannover, Germany; and the Center for Systems Neuroscience (ZSN), Hannover, Germany (N.L., R.D., K.W.).

      Integrated Research and Treatment Center (IFB) Transplantation, Hannover Medical School, Hannover, Germany

      2012

      Medical School Hannover, Hannover, Germany

      2011

      Dept. of NeurologyDept. of Nuclear Medicine Medical School Hannover Germany

      2010

      Medizinische Hochschule Hannover, Abteilung für Neurologie, Hannover, Germany

      Innsbruck Medical University, Austria

      2009

      From the Division of Clinical Neuroscience (H.E., M.W., C.B.), Max Planck Institute of Experimental Medicine, Göttingen, Germany; Center for Neurological Medicine (K.W., R.D.), Hannover Medical School, Hannover, Germany; the Department of Neurology (H.P., M.B., A.K.), University Medical Center Göttingen, Georg-August-University, Göttingen, Germany; the Department of Neurology (D.S., A.W.), University Hospital of Leipzig, Leipzig, Germany; the Department of Neurology (C.W.), University of Duisburg-Essen, Essen, Germany; the Department of Neurology (K.W., H.R.), Stroke Center, University of Technology Dresden, Dresden, Germany; the Department of Neurology (P.D.S., S.S.), University Hospital of Erlangen, Erlangen, Germany; Central Pharmacy (M.B.), University Medical Center Göttingen, Georg-August-University, Göttingen, Germany; Applied Science and Technology (H.B.), Zwingenberg, Germany; Data Management and Biostatistical Services (P.J.), PAREXEL International GmbH, Berlin, Germany; the Department of Neuropsychology and Behavioral Neurobiology (M.H.), University of Bremen, Bremen, Germany; the Department of Neuroradiology (M.K.), University Medical Center Göttingen, Georg-August-University, Göttingen, Germany; the Department of Neurology (W.H.), General Hospital Celle, Celle, Germany; and the Department of Neurology (G.S.), University Hospital Bremen-Mitte, Bremen, Germany.

      2008

      Department of Neurology, Medical School of Hannover, Hannover, Germany

      2007

      Department of Neurology, Medizinische Hochschule Hannover, 30623 Hannover, Germany

      2006

      Neurologische Klinik, Medizinische Hochschule Hannover, 30623 Hannover, Germany.

      Department of Neurology, Hannover University Hospital, Hannover, Germany

      2005

      Department of Neuroradiology, Medizinische Hochschule Hannover, Hannover, Germany

      2004

      Department of Neuroradiology, Medizinische Hochschule Hannover, D-30623 Hannover, Germany

      2003

      Department of Neurology and Clinical Neurophysiology, Medizinische Hochschule Hannover, Germany

      2002

      Department of Neurology, Medizinische Hochschule Hannover, 30623 Hannover, Germany. fax: (49) 511‐532‐3115

      Neurologische Klinik, Medizinische Hochschule Hannover, DE

      2000

      Department of Neurology, Medizinische, Hochschule Hannover, 30623, Hannover, Germany

      1998

      Neurologische Klinik, Medizinische Hochschule Hannover, Hannover, Germany

      1997

      Center for PET and Departments of Neurology and Nuclear Medicine, VA Western New York Healthcare System and SUNY, University at Buffalo, Buifalo. New York. USA, Department of Neurology. Medizlnische Hochschule. Hannover, Germany, and Liver Unit and Laboratory of Neurochemistry. Andre-Viallet Clinical Research Center, Saint-Luc Hospital, Montrbl, QuBbec, Canada

      1996

      Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover, Hannover, Germany

      1995

      Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str.8, 30625, Hannover, Germany

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Karin Weissenborn is among the top experts in the world.
      Concept World rank
      thalamus 004 #1
      increased catabolism dopamine #1
      study phes #1
      detailed workup #1
      plaque embolic #1
      flapping tremor minimal #1
      nscp risk #1
      injection pros #1
      ctcbf values #1
      petcbf measurements #1
      perfectly balanced samples #1
      9 214 patients #1
      2029 8089 years #1
      scspatients higher plasmalevels #1
      background multitude #1
      concomitant cerebral disorder #1
      development metabolictoxic cnscs #1
      features hepatic encephalopathy #1
      cirrhotics pet studies #1
      brain dysfunction life #1
      nscp esus patients #1
      mhe optimal #1
      diagnosing minimal #1
      plaque nscp #1
      superselective placement microcatheter #1
      posttransplant encephalopathy #1
      dysarthria flapping tremor #1
      prognosis sneddon #1
      neuroinflammation neuroreceptor systems #1
      composition cerebral thrombi #1
      mon2 controls #1
      markers atrial disease #1
      liver cirrhosis brain #1
      standardized incidence stroke #1
      2 distinct underlying #1
      toxic cnscs #1
      spect alteration #1
      whc mhe #1
      barely sex #1
      systemic infections event #1
      proven pcnsv #1
      nscp markers #1
      time fkn #1
      modification wada test #1
      neuropsychiatric syndrome recommendations #1
      vulnerabilitycriteria #1
      paperandpencil phes #1
      optimal mhe #1
      brain function pathophysiology #1
      cnscs olt #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Karin Weissenborn

      KOL-Index: 13591

      BACKGROUND: Early inflammation has been suggested as an important factor contributing to unfavorable prognosis after acute ischemic stroke. The present study aimed to clarify the temporal dynamics of discrete inflammatory markers/mediators for future mechanism-targeting anti-inflammatory strategies in ischemic brain damage.

      METHODS: Blood samples of 69 patients with transient ischemic attack or ischemic stroke were taken upon admission and at time points 6, 12 and 24 h, as well as 3 and ...

      Known for Stroke Outcome | Inflammatory Markers | Temporal Profile | Mmp9 Timp1 | Acute Ischemic
      KOL-Index: 12722

      BACKGROUND: In May 2011, an outbreak of Shiga toxin-producing enterohaemorrhagic E coli O104:H4 in northern Germany led to a high proportion of patients developing post-enteritis haemolytic uraemic syndrome and thrombotic microangiopathy that were unresponsive to therapeutic plasma exchange or complement-blocking antibody (eculizumab). Some patients needed ventilatory support due to severe neurological complications, which arose 1 week after onset of enteritis, suggesting an ...

      Known for Escherichia Coli | Severe Neurological | Immunoadsorption Patients | Igg Depletion | Uraemic Syndrome
      KOL-Index: 12377

      BACKGROUND: Ischemic stroke patients are prone to infection by stroke-induced immunodepression. We hypothesized that levels of lipopolysaccharide binding protein (LBP), interleukin-10 (IL-10), IL-6 and C-reactive protein (CRP) are early predictors for the development of stroke-associated infection.

      METHODS: Fifty-six patients with ischemic stroke (n = 51) and transient ischemic attack (TIA) (n = 5) who presented within 6 hours after symptom onset and who were free of detectable infection ...

      Known for Ischemic Stroke | Reactive Protein | Patients Infection | Brain Damage | Lipopolysaccharide Binding
      KOL-Index: 12210

      BACKGROUND: Little is known about the best antiplatelet treatment immediately after ischaemic stroke or transient ischaemic attack (TIA). The EARLY trial aimed to compare outcome in patients given aspirin plus extended-release dipyridamole twice daily either within 24 h of stroke or TIA or after 7 days of aspirin monotherapy.

      METHODS: In 46 stroke units in Germany, patients aged 18 years or more who presented with symptoms of an acute ischaemic stroke that caused a measurable ...

      Known for Ischaemic Stroke | Early Treatment | Symptom Onset | Release Dipyridamole | Patients Aspirin
      KOL-Index: 12069

      BACKGROUND AND PURPOSE: Several retrospective studies suggested that contrast extravasation on CT angiography predicts hematoma expansion, poor outcome, and mortality in primary intracerebral hemorrhage. We aimed to determine the predictive value of contrast extravasation on multidetector CT angiography for clinical outcome in a prospective study.

      METHODS: In 160 consecutive patients with spontaneous intracerebral hemorrhage admitted within 6 hours of symptom onset, noncontrast CT and ...

      Known for Contrast Extravasation | Primary Intracerebral Hemorrhage | Poor Outcome | Computed Tomography | Multidetector Angiography
      KOL-Index: 11725

      OBJECTIVE: To evaluate the effect of different treatment strategies on enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome.

      DESIGN: Multicentre retrospective case-control study.

      SETTING: 23 hospitals in northern Germany.

      PARTICIPANTS: 298 adults with enterohaemorrhagic E coli induced haemolytic uraemic syndrome.

      MAIN OUTCOME MEASURES: Dialysis, seizures, mechanical ventilation, abdominal surgery owing to perforation of the bowel or bowel necrosis, and ...

      Known for Haemolytic Uraemic Syndrome | Treatment Strategies | Escherichia Coli | O104 H4 | Dialysis Seizures
      KOL-Index: 10971

      OBJECTIVE: In this study, perfusion CT and diffusion-weighted magnetic resonance imaging (DWI) were compared as means of assessing the ischemic brain in hyperacute stroke.

      METHODS: Twenty patients with ischemic stroke underwent perfusion computed tomography (CT) and magnetic resonance imaging (MRI) studies <3 hours after stroke onset. Cerebral blood flow thresholds were used to delineate the ischemic lesion, penumbra, and infarct. Correlations between the volume of the hypoperfused ...

      Known for Ischemic Stroke | Computed Tomography | Resonance Imaging | Infarct Volume | Image Enhancement
      KOL-Index: 10692

      BACKGROUND: Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for thrombolysis with recombinant tissue-type plasminogen activator (rt-PA). In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth.

      AIMS: To provide insights into the clinical use of idarucizumab in patients ...

      Known for Ischemic Stroke | Intracranial Hemorrhage | Idarucizumab Patients | Dabigatran Treatment | Antibodies Monoclonal
      KOL-Index: 9774

      BACKGROUND AND PURPOSE: Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment of patients with ischemic stroke. Although EPO has been considered to be a safe and well-tolerated drug over 2 decades, recent studies have identified increased thromboembolic complications and/or mortality risks on EPO administration to patients with cancer or chronic kidney disease. ...

      Known for Acute Ischemic Stroke | Recombinant Human Erythropoietin | Systemic Thrombolysis | Epo Administration | Clinical Trial
      KOL-Index: 9413

      Objective- Gut microbiota-dependent metabolites, in particular trimethylamine N-oxide (TMAO), have recently been reported to promote atherosclerosis and thrombosis. Here, we examined for the first time the relation of TMAO and the risk of incident cardiovascular events in patients with recent first-ever ischemic stroke in 2 independent prospective cohorts. Moreover, the link between TMAO and proinflammatory monocytes as a potential contributing factor for cardiovascular risk in stroke ...

      Known for Cardiovascular Events | Gut Microbiota | Tmao Levels | Risk Stroke | Hazard Ratio
      KOL-Index: 9352

      BACKGROUND: Hepatic encephalopathy is considered to be mainly caused by increased ammonia metabolism of the brain. If this hypothesis is true, cerebral glucose utilisation, which is considered to represent brain function, should be closely related to cerebral ammonia metabolism. The aim of the present study was to analyse whether cerebral ammonia and glucose metabolism in cirrhotic patients with early grades of hepatic encephalopathy are as closely related as could be expected from ...

      Known for Cirrhotic Patients | Magnetic Resonance | Hepatic Encephalopathy | Cerebral Ammonia | Glucose Metabolism
      KOL-Index: 9303

      Asymmetric dimethylarginine (ADMA) and l-homoarginine (hArg) are l-arginine (Arg) metabolites derived from different pathways. Protein arginine N-methyltransferase (PRMT) and subsequent proteolysis of proteins containing methylarginine residues release ADMA. Arginine:glycine amidinotransferase (AGAT) converts Arg to hArg and guanidinoacetate (GAA). While high concentrations of ADMA and low concentrations of hArg in the blood have been established as cardiovascular risk markers, the ...

      Known for Harg Adma | Nitric Oxide | Stroke Patients | Arginine Arg | Media Thickness
      KOL-Index: 8952

      AIM: Increased levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been observed in patients with cardiovascular risk factors and atherosclerosis and in patients with a history of stroke. The role of ADMA and its analogue symmetric dimethylarginine (SDMA) in acute ischemic stroke is yet unclear. We hypothesized that plasma dimethylarginine levels increase in the hyper-acute phase after ischemic stroke and that their time course is related ...

      Known for Plasma Dimethylarginine Levels | Adma Sdma | Ischemic Stroke | Asymmetric Dimethylarginine | Endogenous Inhibitor
      KOL-Index: 8716

      OBJECTIVE: Fatigue, mood disturbances and cognitive dysfunction are frequent in patients infected with hepatitis C virus (HCV) who have mild liver disease. The reason is still unclear. The present study aims to gain more insight into the pathomechanism by combining an extensive neuropsychological examination with magnetic resonance spectroscopy in four different brain regions in a patient group covering the whole spectrum of neuropsychiatric findings in patients afflicted with HCV who ...

      Known for Hcv Infection | White Matter | Choline Creatine | Basal Ganglia | Neuropsychiatric Symptoms
      KOL-Index: 8690

      OBJECTIVES: Repetitive transcranial magnetic stimulation (rTMS) has been tried therapeutically in a variety of neuropsychiatric disorders. Both, inhibition and activation of cortical areas may be achieved using different stimulation parameters. Using low-frequency rTMS (0.9 Hz), inhibition of cortical areas can be observed.

      METHODS: In the present study, 38 right-handed, healthy, normotensive subjects (aged 21-50 years, mean 30.2 years, SD=4.9; 17 women) were enrolled. Twenty-five ...

      Known for Transcranial Magnetic | Middle Cerebral | Flow Velocity | Active Rtms | Artery Blood

      Key People For Hepatic Encephalopathy

      Top KOLs in the world
      #1
      Peter Ferenci
      chronic hepatitis hepatic encephalopathy wilson disease
      #2
      Kevin Daniel Mullen
      hepatic encephalopathy chronic hepatitis portacaval shunt
      #3
      Juan Córdoba
      hepatic encephalopathy liver transplantation brain edema
      #4
      Roger F Butterworth∗
      hepatic encephalopathy acute liver failure thiamine deficiency
      #5
      Karin Weissenborn
      hepatic encephalopathy liver transplantation ischemic stroke
      #6
      Andrés T Blei
      brain edema hepatic encephalopathy acute liver failure

      Department of Neurology, Hannover Medical School, Hannover, Germany. | Department of Neurology, Hannover Medical School, Germany. (G.M.G., N.B., J.E., A.L., M.M.G., T.v.G., H.W., K.W., R.S.). | Department of Neurology, Hannover Medical School, German

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.